Your browser doesn't support javascript.
loading
Therapeutic Plasma Exchange in Catastrophic Antiphospholipid Syndrome (CAPS): A Rare Case Report and Literature Review.
Bereanu, Alina-Simona; Pisaltu, Teofil; Bereanu, Rareș; Vintila, Bogdan; Codru, Ioana; Chicea, Liana; Crisan, Ovidiu; Cainap, Calin; Cainap, Simona; Sava, Mihai.
Afiliación
  • Bereanu AS; Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania; rares.bereanu@ulbsibiu.ro.
  • Pisaltu T; County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.
  • Bereanu R; County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.
  • Vintila B; Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.
  • Codru I; Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.
  • Chicea L; County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.
  • Crisan O; Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.
  • Cainap C; County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.
  • Cainap S; Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.
  • Sava M; County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.
In Vivo ; 37(4): 1914-1919, 2023.
Article en En | MEDLINE | ID: mdl-37369472
ABSTRACT
BACKGROUND/

AIM:

Catastrophic antiphospholipid syndrome (CAPS) may be the first manifestation ("de novo") of antiphospholipid syndrome (APS) or a complication in the clinical course of patients known to have this syndrome. Approximately 40% of patients had an associated autoimmune disease, mainly, systemic lupus erythematosus (SLE). The trigger can be one of the following infections, surgical interventions, neoplasms, pregnancy, discontinuation of anticoagulant treatment, and others. CAPS is a medical emergency in which early identification and prompt initiation of aggressive therapy is extremely important. According to the Guidelines for the use of Therapeutic Apheresis in Clinical Practice developed by the American Society for Apheresis (ASFA), last updated in April 2023, in CAPS, the indication for therapeutic plasma exchange (TPE) is category I, grade 2C. CASE REPORT We present a case of probable CAPS secondary to systemic lupus erythematosus (SLE) in an elderly patient in whom clinical and biological improvement was achieved through a multidisciplinary approach and prompt initiation of TPE. Because TPE is considered first-line therapy in CAPS, we initiated the procedure as soon as the attending rheumatologist raised this suspicion. Four plasmapheresis sessions were performed in the Intensive Care Unit. We used TPE by membrane filtration. Following the therapeutic intervention with TPE, corticotherapy (Solumedrol in puls-therapy), cyclophosphamide and anticoagulant treatment, the evolution was favourable, with clinical and biological improvement.

CONCLUSION:

The prompt initiation of TPE, because of the suspicion of CAPS, increases the chances of a favourable evolution.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Lupus Eritematoso Sistémico Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Lupus Eritematoso Sistémico Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Aged / Humans Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article